Sana Biotechnology
SANA
125 hedge funds and large institutions have $770M invested in Sana Biotechnology in 2022 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 40 increasing their positions, 29 reducing their positions, and 7 closing their positions.
143% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 7
38% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 29
8% more funds holding
Funds holding: 116 → 125 (+9)
1.23% more ownership
Funds ownership: 66.22% → 67.45% (+1.2%)
5% less capital invested
Capital invested by funds: $808M → $770M (-$37.8M)
11% less call options, than puts
Call options by funds: $92K | Put options by funds: $103K
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$8.08M |
| 2 |
Millennium Management
New York
|
+$5.75M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.68M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.4M |
| 5 |
ABG
Ally Bridge Group
New York
|
+$5.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$14.8M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$5.14M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.91M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$1.89M |
| 5 |
Morgan Stanley
New York
|
-$1.67M |
SANA Hedge Fund Activity: Q3 2022 in Review
125 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Sana Biotechnology (SANA) for Q3 2022, worth a combined $770M — down 4.7% from $808M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new SANA positions and 7 closed out — a net gain of 10 holders — while 40 added to existing stakes and 29 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $8.08M. The largest seller was State Street, cutting an estimated $14.8M.
- 125 institutional investors held Sana Biotechnology (SANA) as of Q3 2022, up from 116 in Q2 2022.
- Funds reported $770M of Sana Biotechnology stock for Q3 2022, down 4.7% quarter-over-quarter.
- 17 funds opened new Sana Biotechnology positions in Q3 2022 and 7 closed out, a net change of +10 holders.
- The largest Sana Biotechnology buyer in Q3 2022 was Citadel Advisors, an estimated $8.08M added.
- The largest Sana Biotechnology seller in Q3 2022 was State Street, an estimated $14.8M sold.
Based on aggregated 13F filings for Q3 2022.